Compare McKesson Corporation (MCK) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Nokia Corp — how do they compare? McKesson Corporation trades at $878 (market cap $105.14B), while Nokia Corp trades at $10.29 (market cap $53.00B). The key difference: McKesson Corporation is the larger of the two by market cap, and Nokia Corp pays the higher dividend (1.73%). Which is the better fit depends on your goals.
| MCK | NOK | |
|---|---|---|
Market Cap | $105.14B | $53.00B |
Sector | Health | Technology |
52-Week High | $995.69 | $16.83 |
52-Week Low | $659.01 | $4.13 |
Enterprise Value | $111.67B | $50.95B |
Dividend Yield | 0.42% | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.
MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.
Nokia (NOK) trades at $10.315, up 13.1% on the day, reflecting positive momentum. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, revenue was $19.89B in 2025 with a net income margin of 3.47%, while the P/E ratio of 68.07 suggests a premium valuation. Recent earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026. News highlights focus on AI infrastructure growth driving demand.
The outlook is cautiously optimistic, supported by strong analyst buy consensus (59.61%) and AI-driven demand tailwinds. However, risks include competitive pressures in telecom, volatility in cash flows, and the high P/E ratio indicating stretched valuations. Investment appeal hinges on successful execution in AI and cloud segments offsetting traditional market challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
